Welcome to CONMED’s Fourth Quarter Fiscal Year 2024 Earnings Conference Call
Company Participants:
– Pat Beyer: Chief Executive Officer & President
– Todd Garner: Executive Vice President and Chief Financial Officer
Conference Call Participants:
– Rick Wise: Stifel
– Robbie Marcus: JPMorgan
– Vik Chopra: Wells Fargo Corporate & Investment Banking
– Young Li: Jefferies
– Travis Steed: BofA Securities
Thank you for standing by, and welcome to CONMED’s Fourth Quarter Fiscal Year 2024 Earnings Conference Call. Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, its plans, and objectives.
The Q4 2024 Results Conference Call for CONMED Corporation (NYSE: CNMD) took place on February 5, 2025, at 4:30 PM ET. The executives present during the call were Pat Beyer, the CEO & President, and Todd Garner, the Executive Vice President and CFO.
During the call, they discussed the financial performance of the company in the fourth quarter of the fiscal year 2024. They provided insights into their plans and objectives moving forward, giving investors and analysts a better understanding of CONMED’s position in the market.
Effects on Individuals:
For individual investors, the Q4 earnings report can provide valuable information about the company’s financial health and future prospects. It can help them make informed decisions about their investments in CONMED Corporation.
Effects on the World:
As a leading medical technology company, CONMED’s performance has implications for the healthcare industry and patients around the world. Their innovative products and solutions impact the quality of medical care provided to millions of people globally.
Conclusion:
The Q4 2024 Earnings Conference Call for CONMED Corporation shed light on the company’s financial performance and future outlook. With strong leadership and strategic planning, CONMED continues to be a key player in the medical technology industry, influencing both individual investors and the global healthcare landscape.
